Medicaid Hepatitis C Subscription Model Update
Medicaid Subscription Model Overview

• Unlimited quantity of hepatitis C treatment at no more than a fixed cost for the state

• Preferred agent is the authorized generic of Epclusa (sofosbuvir/velpatasvir), with no requirement for prior authorization

• Began July 15, 2019
Cost Comparisons

• To gauge performance of the model, we can also look at cost

• Specific rebate amounts are confidential, but we can look at comparisons to alternative strategies

• Comparison 1: Current hepatitis C subscription model (AG Epclusa) versus the next best “subscription” offer from that solicitation (Mavyret)

• Comparison 2: Current hepatitis C subscription model (AG Epclusa) versus the best available offer through our normal preferred drug list development process
Comparison 1

• Current hepatitis C subscription model (AG Epclusa) versus the next best “subscription” offer from that solicitation (Mavyret)

• For year 1, the current hepatitis C subscription model resulted in lower cost by an estimated $19.1M
Comparison 2

• Current hepatitis C subscription model (AG Epclusa) versus the best available offer through our normal preferred drug list development process

• For year 1, the current hepatitis C subscription model resulted in lower cost by $29.5M
Summary

• The current subscription model (AG Epclusa) resulted in lower cost relative to the two next best alternatives